

Press release

Lund April 25, 2023

## Scandinavian ChemoTech's subsidiary in the USA for Animal Care receives significant order from veterinary hospital chains

**Vetiqure North America (VQ Animal Care INC) receives a significant order for TSE technology from Sage Veterinary Center (SVC) in San Fransisco, California, which amounts to approximately 28,000 USD.**

SVC is a group of veterinary hospitals consisting of five clinics offering unique facilities and the latest surgical and diagnostic technologies. SVC's surgeons perform a range of advanced procedures that include soft tissue, cancer, orthopedic and neurological surgeries. The surgeons collaborate with all departments within SVC to ensure that pets have access to the most advanced medical and surgical care.

In a comment, Scandinavian ChemoTech's CEO, Mohan Frick, says:

"SVC is a high-profile veterinary hospital chain, which is why this order will serve as an important reference for future discussions with other similar actors. The fact that SVC is owned by the much larger NVA with 1400 hospitals means that it can also open up many new opportunities going forward. We look forward with confidence to starting the collaboration with SVC."

This information is such information that Scandinavian ChemoTech AB is obliged to make public according to the EU's market abuse regulation. The information was provided, through the agency of the contact person, for publication on 2023-04-25 at 17:20 CEST.

*For more information, please contact:*

Mohan Frick, CEO

Tel: +46 (0)10-218 93 00

E-mail: [ir@chemotech.se](mailto:ir@chemotech.se)

**Certified Adviser:** Redeye AB, Tel: +46 (0)8 - 121 576 90

E-mail: [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)

### Scandinavian ChemoTech AB

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology.

ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: [www.chemotech.se](http://www.chemotech.se).